Clinical Research Directory
Browse clinical research sites, groups, and studies.
Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients
Sponsor: Tanta University
Summary
Major depressive disorder (MDD) is one of the most common psychiatric disorders with serious socioeconomic consequences on daily life and health care costs. Despite the advent of newer antidepressants that target monoamine pathways, nearly 50% of patients have no response to first-line antidepressant therapy. Thus, a combination of medications with different strategies at the beginning of treatment could provide further therapeutic benefits to MDD patients
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2025-03-01
Completion Date
2026-08-20
Last Updated
2025-03-18
Healthy Volunteers
No
Conditions
Interventions
Fluoxetine
Fluoxetine is an antidepressant and belongs to a group of medicines known as selective serotonin reuptake inhibitors (SSRIs)
Roflumilast
Roflumilast is the first drug targeting PDE4 that was marketed for treatment of chronic obstructive pulmonary disease (COPD) with relatively weak potency inducing nausea and vomiting
Placebo
Placebo
Locations (1)
Tanta Unuversity
Tanta, Egypt